Podcasts

In this podcast episode, we discuss the journey of novel modalities in rare disease treatment to patients, particularly advancements in oncology and the increasing role of patients' families in accelerating R&D.

In the current industry landscape, API quality can make or break a drug product. LGM Pharma stands out by treating supplier relationships as strategic partnerships rather than transactions. In this interview with Pharmaceutical Technology, Shailesh Vengurlekar and Diem Hoang share LGM’s rigorous, multi-step process for evaluating, approving, and continuously monitoring API manufacturers—highlighting the company’s collaborative approach that prioritizes transparency, and patient safety.

In this podcast episode, we discuss sustainable approaches to such equipment and materials as medical propellants, flow sensor technology, and walk-in chambers, plus the critical role of women in elevating and accelerating development in these areas.

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

The growing development of new biotherapeutic modalities will rely heavily on automation and progressive technologies.

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage, as viewed by five industry experts who recently exhibited at CPHI Milan.

Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.

In this podcast episode, we discuss both the challenges of and the progress made so far by the biopharma industry toward non-parenteral means of delivering biologic drugs.

In this sponsored episode, Jörg Zimmermann from Vetter chats about fill/finish advances.

There is not a syringe solution that fits all challenges. In this Podcast, Enrico Barichello, Product Manager for Syringe Platform in Stevanato Group, and Alan Xu, Product Manager for Analytical Services in Stevanato Group's Technology Excellence Centers, discuss the best strategies to select the right pre-filled syringe (PFS) based on the key needs of combination products and illustrate how introducing analytical services from an early stage can help customers reach the market faster by avoiding costly product revalidations or reformulations. Don’t miss out on the opportunity to be part of the conversation driving the PFS industry forward.

Join this insightful dialogue where we’ll explore advancements in the evolving world of cell and gene therapy analysis with Daniel Galbraith, Chief Scientific Officer of Solvias. Daniel shares insights from the forefront of drug development, including the complexities of development and commercialization, the financial dynamics of new therapies and changing regulatory landscapes. This podcast provides an enlightening conversation about the dynamic cell and gene therapy analysis space and provides a unique look at the innovations driving the industry forward.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

In this podcast, hear from our global experts Martin Gonzalez, PHD and Katharine Sparhawk as they share exclusive details of Pfizer CentreOne’s sterile injectable capabilities from both a technical expertise and business development point of view. Our experts will explore key topics including emerging sterile injectable trends, the company’s approach to flexibility in capacity planning and emerging trends that are shaping the development of complex biologics like ADCs.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Polyimide materials, as Kapton®, are widely used for flexible electronics substrates or as insulators, thanks to their wide range of thermal stability as well as excellent dielectric and mechanical properties. However, there are limitations in their processability and employment in new technologies due to their low solubility and deep amber staining, resulting from charge transfer interactions established between polymer rigid chains. Currently, researchers are focusing on designing resins with excellent thermal and chemical stability, transparent and colorless with a high processability in terms of viscosity and solubility. However, balancing among all those properties for this class of materials remains a big challenge today, as some of these properties seem to exclude others. In this episode, the focus will be on aliphatic anhydrides, which play a key role for the final polyimide’s properties enhancement. This will be explained by B.Sc. Sara Greco, a chemist working on this topic (as part of her master's thesis) in the R&D department of Valsynthese, a Swiss CDMO specialized in hazardous chemistry.

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Dr. Luca Mantilli, R&D chemist at Valsynthese, the fine chemical unit of the Société Suisse des Explosifs Group (SSE), will guide you through the journey that Valsynthese as CDMO has done in phosgenation. The advantages and synthetic possibilities of phosgene, an extremely versatile reagent, will be highlighted with respect to other alternatives, same as the safety measures needed when working with such hazardous building blocks.

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.

Tom Fletcher, director of Research and Development at FUJIFILM Irvine Scientific; and Bob Newman, PhD, chief scientific director at FUJIFILM Irvine Scientific, discuss formulation, specifically with how to prepare culture media for use, single use technologies, and automations to create closed systems in cell/gene therapies with former Pharmaceutical Technology editor Jill Murphy.

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

In this episode of the Drug Solutions Podcast, industry experts discuss the challenges and advantages of the digitalization trend in the biopharma industry, with particular emphasis on the impacts to biomanufacturing.

In this episode of the Drug Solutions Podcast, Shawn Liu, the president and CEO of Avirmax, relates his experience in entering the cell and gene therapy manufacturing space and how he began his own startup cell and gene therapy CDMO.

Jet milling is a well-established particle engineering technique for producing micronized powders with controlled particle size distribution and increased surface area. This makes them suitable for inhalation drug delivery. However, successful implementation of jet milling requires a robust Quality by Design (QbD) approach that ensures the critical quality attributes of the micronized particles are maintained throughout the process development. This episode will cover the principles and intricacies of the jet milling process. It will also highlight some of the challenges when micronizing for inhalation delivery, and give some possible solutions. A case study will demonstrate a reliable process development strategy using a QbD approach for micronizing nilotinib, an API with potential for the treatment of severe chronic asthma. It will highlight the significance of implementing a QbD approach, and its benefits in process development. Overall, this presentation aims to provide valuable insights into the jet milling process and QbD approach for inhalation drug delivery and their potential applications in drug development.

An mRNA conversation about the recent past, current hot topics, and probable future.